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Objectives. We sought to evaluate whether troponin T might be
used for identification of patients with unstable coronary artery
disease in whom treatment with low molecular weight heparin is
beneficial.
Background. Early identification of subgroups with differences
in response to a certain treatment is important to optimize the
utilization of different therapeutic approaches.
Methods. Nine-hundred seventy-one patients with unstable
coronary artery disease who participated in a trial of the low
molecular weight heparin dalteparin (Fragmin) and who provided
blood samples were classified into subgroups according to tropo-
nin T level. In the short-term phase all patients received subcu-
taneous dalteparin/placebo twice daily for 6 days. During the
long-term phase they continued with daltparin/placebo once daily
for another 5 weeks.
Results. In the short-term phase, dalteparin reduced the inci-
dence of death or myocardial infarction from 2.4% to 0% (p 5
0.12) and from 6.0% to 2.5% (p < 0.05) in 327 and 644 patients
with troponin T levels <0.1 and >20.1 mg/liter, respectively.
During long-term treatment there was an increasing difference
between the placebo and dalteparin group in those with troponin
T levels >20.1 mg/liter, in whom the incidences at 40 days were
14.2% and 7.4%, respectively (p < 0.01). In contrast, no beneficial
effect of the long-term treatment could be demonstrated in those
with troponin T levels <0.1 mg/liter (4.7% vs. 5.7%).
Conclusions. Elevation of troponin T identifies a subgroup of
patients in whom prolonged antithrombotic treatment (e.g., with
dalteparin) is beneficial.
(J Am Coll Cardiol 1997;29:43–8)
q1997 by the American College of Cardiology
In patients with unstable coronary artery disease (CAD), i.e.,
unstable angina (UA) and non–Q wave myocardial infarction
(MI), one of the main aims of treatment is prevention of new
cardiac events, which are frequent during the subsequent
weeks and months (1,2). In the Fragmin in Unstable Coronary
Artery Disease (FRISC) study, inhibition of coagulation by the
low molecular weight heparin, dalteparin (Fragmin), in addi-
tion to platelet inhibition by aspirin, was shown to reduce the
event rate in unstable CAD in the short-term phase and
possibly also during long-term treatment (3). However, the
large population with unstable CAD is heterogeneous, regard-
ing both the severity of the underlying CAD and the prognosis
(4–6). Therefore, early risk stratification might be essential to
select the most beneficial and cost-effective therapeutic ap-
proach for the individual patient. Several studies, including a
previous report from the FRISC troponin T substudy, have
shown that patients with even minor elevation of troponin T
have an increased risk for subsequent cardiac events (7–9). We
have speculated that there might be differences in the patho-
genic mechanisms in unstable CAD patients with and without
troponin T elevation, which might also affect the response to
antithrombotic treatment. However, so far no study has dem-
onstrated any difference in the effect of any therapeutic
approach between subgroups of patients with unstable CAD.
Accordingly, in the present prespecified substudy we evaluated
prospectively whether the effect of low molecular weight
heparin differed between patients with different levels of
troponin T, and hence, if troponin T levels might be used to
identify patients with unstable CAD who benefit from short- or
long-term treatment, or both, with low molecular weight
heparin.
Methods
Patients. This was a substudy of the FRISC trial—a
double-blind, randomized, placebo-controlled trial of low mo-
lecular weight heparin (dalteparin sodium [Fragmin, Pharma-
cia AB, Sweden]) in patients with unstable CAD, including
1,506 patients at 23 hospitals in Sweden between May 1992 and
October 1994. Details of the FRISC protocol have been
reported (3). Eligible for inclusion were men .40 years or
women 1 year after menopause who were admitted to the
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hospital because of chest pain, with their last episode within
72 h. All patients had to fulfil at least one of the following
anamnestic criteria: newly developed or increased angina
pectoris or angina at rest during the previous 2 months or
ongoing chest pain suggestive of MI; and at least one of the
following electrocardiographic (ECG) criteria: transient or
persistent pathologic ST segment depression $0.1 mV or T
wave inversion in at least two adjacent leads without pathologic
Q waves, believed to indicate ischemia. Exclusion criteria were
conditions with an increased risk of bleeding, indication for
thrombolysis, new Q wave, left bundle branch block, pace-
maker, suspected endomyopericarditis, cardiomyopathy, sig-
nificant aortic valve disease, uncontrolled hypertension or
hypotension, coronary artery bypass grafting or percutaneous
transluminal coronary angioplasty planned or performed
within the last 3 months, anemia, renal failure, hepatic failure,
fever $398C, serious intercurrent disease, hypersensitivity to
heparin or low molecular weight heparin and unwillingness or
inability to participate.
In 15 hospitals the protocol included a blood sampling
schedule. The present substudy included all 971 patients in
whom one blood sample for analysis of troponin T was
obtained at inclusion.
Randomization and management. After admission all pa-
tients without a contraindication received oral aspirin (75 mg
once daily), beta-blockers and organic nitrates and calcium
antagonists as needed. The randomization was done in blocks
within each center. Treatment was to start as early as possible
after admission. Double-blind, placebo-controlled, random-
ized treatment with dalteparin/placebo was given as a subcu-
taneous injection twice daily at a dose of 120 U/kg body weight
(maximal dose 10,000 U) for the first 5 to 7 days (short-term
phase) and then once daily at a dose of 7,500 U for another
5 weeks (long-term phase). Heparin infusion, coronary angiog-
raphy and revascularization were recommended in case of
refractory or incapacitating angina despite medical treatment
or after signs of severe ischemia on an exercise test. All
therapeutic decisions were made without knowledge of the
patients’ troponin T levels.
The study was approved by the local ethics committee and
all enrolled patients provided witnessed informed consent.
Evaluation of index event and end points. The episode that
caused the enrollment in the study (index event) was retro-
spectively classified as MI or UA according to the maximal
levels of available cardiac enzymes (serum creatine kinase
[CK], serum CK-MB fraction or serum aspartate transami-
nase) obtained and analyzed at the local hospital immediately
after the episode.
All patients were followed up while in the hospital and
thereafter by outpatient visits after 6 weeks and 5 to 6 months.
All primary end points (i.e., death and nonfatal MI) were
classified by an independent end point committee. Myocardial
infarction was defined by conventional World Health Organi-
zation criteria (10), satisfying two of the following three
criteria: 1) severe ischemic chest pain of at least 20 min
duration; 2) a diagnostic ECG; or 3) an increase in cardiac
enzymes above the upper reference level at the local hospital
in at least two consecutive samples.
Blood samples and laboratory methods. A venous blood
sample for analyses of plasma troponin T was obtained at study
inclusion. Blood was collected in an EDTA-containing tube
and centrifuged, and plasma was frozen in aliquots and stored
for subsequent analysis. Troponin T was determined by the
Enzymun-Test system (Boehringer-Mannheim, Germany)
(11). The lower detection limit is 0.04 mg/liter according to the
manufacturer, and the upper reference level in healthy blood
donors is 0.06 mg/liter (12). All analyses were done at one
laboratory (Department of Clinical Chemistry, University of
Uppsala, Sweden) and without knowledge of the patients’
diagnosis and outcome. The between-day coefficient of varia-
tion over 4 months (n 5 99) at our laboratory was 10.2% and
5.1% at a level of 0.28 and 6.10 mg/liter, respectively.
Statistical analysis. All analyses were performed according
to the intention to treat principle. Differences in proportions
were judged by the chi-square test. The relative risk (RR) ratio
and the 95% confidence interval (CI) were calculated as
appropriate. For nonparametric unrelated data, the Mann-
Whitney U test was used. The cumulative hazard curves were
constructed using the Kaplan-Meier method. The end points
were death or nonfatal MI. Statistical assessment was per-
formed using the log-rank test. Testing for an interaction
between dalteparin/placebo treatment and troponin T level on
the risk of death or MI was done by a multiple logistic
regression analysis. A significant difference was considered to
exist at the p , 0.05 level. All statistical analyses were
performed by a computer utilizing the SPSS system 6.1 (Sta-
tistical Package for the Social Sciences, 1994).
Results
General findings. The clinical characteristics at inclusion
of the 488 and 483 patients in the placebo and the dalteparin
group, respectively, were very similar to those in the main study
(3). There were no significant differences between the two
groups, except for a slightly higher proportion of congestive
heart failure in the dalteparin group (10% vs. 7%). The end
point rates were also almost exactly the same as those in the
main study (3). On day 6, after completion of the short-term
phase of treatment, death or MI had occurred in 8 (1.7%) and
23 (4.7%) patients in the dalteparin and placebo groups,
respectively (RR 0.35, 95% CI 0.16 to 0.78, p , 0.01).
Immediately before the termination of the long-term phase of
Abbreviations and Acronyms
CAD 5 coronary artery disease
CI 5 confidence interval
MI 5 myocardial infarction
RR 5 relative risk
UA 5 unstable angina
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treatment, on day 40, the number of deaths or MIs was 33
(6.8%) in the dalteparin group and 53 (10.9%) in the placebo
group (RR 0.63, 95% CI 0.41 to 0.95, p, 0.05). However, after
150 days no significant difference between the two groups
remained—death or MI had occurred in 66 dalteparin-treated
patients (13.7%) and 75 patients who received placebo
(15.4%) (RR 0.89, 95% CI 0.65 to 1.21, p 5 0.45).
Compliance with the study treatment was good, only 7.8%
and 10.6% of the patients in the placebo and dalteparin
groups, respectively, terminated the injections prematurely at
their own request.
Effects of dalteparin treatment in relation to troponin T
level. To study the treatment effect of dalteparin in relation to
troponin T, the patients were classified into tertiles of the
troponin T level at inclusion, i.e., below the 33rd percentile
(,0.1 mg/liter), between the 33rd and 66th percentile (0.1 to
0.64 mg/liter) and above the 66th percentile ($0.64 mg/liter).
During the short-term phase of treatment, the occurrence of
death or MI was lower in the dalteparin group compared with
the placebo group in all troponin T tertiles—0% and 2.4%
(p5 0.12), 1.9% and 6.9% (p5 0.03) and 3.0% and 5.0% (p5
0.34), in the lowest, middle and highest tertile, respectively. At
the end of the long-term treatment, on day 40, there was no
beneficial effect in the lowest troponin T tertile on the inci-
dence of death or MI in the dalteparin compared with the
placebo group—5.7% versus 4.7% (p 5 0.68). However, there
seemed to be a similar decrease in death or MI, from 12.6% to
5.7% (p 5 0.03) and from 15.7% to 8.9% (p 5 0.06), in the
middle and highest tertiles, respectively. Thus, for all the
further analyses the patients were classified according to
troponin T level ,0.1 and $0.1 mg/liter.
The clinical characteristics of the placebo and dalteparin
groups, respectively, in patients with troponin T levels ,0.1
and $0.1 mg/liter, respectively, are shown in Table 1. There
were no significant differences in clinical characteristics be-
tween the placebo and dalteparin groups within each troponin
T subset. In patients with a troponin T level $0.1 mg/liter, the
difference in the end point rate between the placebo and
dalteparin groups was already significant after the short-term
phase, and seemed to further increase during the long-term
treatment. In contrast, in patients with a troponin T level ,0.1
mg/liter, there was no difference between the dalteparin and
placebo groups during long-term treatment (Table 2, Fig. 1).
The interaction between treatment and troponin T level and
troponin T level alone, but not the treatment alone, remained
as statistically significant indicators of the risk of death or MI
Table 1. Clinical Characteristics of the Study Group (n 5 971)
Baseline Variables
tn-T ,0.1 mg/liter tn-T $0.1 mg/liter
Placebo
(n 5 170)
Dalteparin
(n 5 157)
Placebo
(n 5 318)
Dalteparin
(n 5 326)
Male 96 (57) 86 (55) 221 (70) 224 (69)
Age (yr) 68 (62–75) 69 (62–75) 71 (64–76) 70 (63–75)
Previous heart failure 12 (7) 19 (12) 20 (6) 31 (10)
Previous stroke 4 (2) 7 (5) 10 (3) 18 (6)
Hypertension 53 (31) 58 (37) 106 (33) 103 (32)
Diabetes 20 (12) 16 (10) 35 (11) 51 (16)
Current smoking 30 (18) 24 (15) 61 (19) 68 (21)
Delay (h)* 22 (14–32) 24 (15–32) 25 (14–37) 24 (15–34)
History of CAD
Previous MI 50 (29) 46 (29) 89 (28) 91 (28)
Rest angina the preceding week 75 (44) 65 (41) 163 (51) 169 (52)
Inclusion diagnosis
UA/non–Q wave MI 162/7 (96/4) 156/1 (99/1) 137/181 (43/57) 136/190 (42/58)
Medication on admission
Aspirin 65 (38) 70 (45) 97 (31) 103 (32)
Beta-blocker 61 (36) 63 (40) 122 (38) 113 (35)
Calcium inhibitor 39 (23) 42 (27) 70 (22) 68 (21)
Long-term nitrates 52 (31) 46 (29) 79 (25) 84 (26)
Diuretics 40 (24) 40 (26) 68 (21) 63 (19)
ACE inhibitor 17 (10) 20 (13) 19 (6) 29 (9)
Digoxin 11 (7) 19 (12) 12 (4) 17 (5)
Rest ECG at inclusion
ST segment depression and T wave inversion 66 (39) 62 (40) 154 (49) 154 (48)
Only ST segment depression 21 (12) 20 (13) 59 (19) 58 (18)
Only T wave inversion 82 (49) 72 (47) 101 (32) 110 (34)
Troponin T at inclusion (mg/liter) 0.04 0.04 0.63 0.69
(0.04–0.06) (0.04–0.06) (0.25–1.6) (0.25–1.7)
*Time from onset of chest pain until inclusion. Data presented are median values (25th to 75th percentile) or number
(%) of patients. ACE 5 angiotensin-converting enzyme; CAD 5 coronary artery disease; ECG 5 electrocardiogram;
MI 5 myocardial infarction; tn-T 5 troponin T; UA 5 unstable angina.
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after 40 days in a multivariate logistic regression analysis
(Table 3). The rate of revascularization in the placebo and
dalteparin groups on day 40 in patients with a troponin T level
$0.1 mg/liter was 18% and 12% (p, 0.05), respectively, and in
patients with a troponin T level ,0.1 mg/liter, 21% and 18%
(NS), respectively. After termination of the randomized treat-
ment the difference in deaths or MI between the dalteparin
and placebo groups of patients with a troponin T level $0.1
mg/liter slowly decreased and was not statistically significant at
the last follow-up visit, after 150 days (Table 2).
If the analysis was restricted to only those with UA as the
inclusion event (n 5 591) the relative risks for death or MI on
day 40 with dalteparin compared with placebo were in the
same range as in the whole population, although the confi-
dence intervals were broader. In those with a troponin T level
,0.1 mg/liter (n 5 318), the rate of death or MI after 40 days
was 5.8% and 4.3% in the dalteparin and placebo groups,
respectively (RR 1.34, 95% CI 0.51 to 3.50). In those with a
troponin T level $0.1 mg/liter (n 5 273), the corresponding
rate of death or MI was 7.4% and 10.9% (RR 0.67, 95% CI
0.31 to 1.44), respectively.
Discussion
Unstable CAD is an increasing reason for hospitalization in
the Western world, and considerable resources are needed for
evaluation and treatment of these patients (13). The syndrome
still implies a high risk for subsequent cardiac events (1,2),
despite considerable progress in treatment in the last decade
(1,14–16). Because the unstable CAD population is heteroge-
neous, the treatment should ideally be tailored according to
proper considerations about prognosis and underlying patho-
physiology. Several noninvasive methods have been proposed
for identification of subgroups with high and low risk, e.g.,
exercise test, Holter ST segment monitoring, thallium scintig-
raphy, stress echocardiography and biochemical markers (7–
9,17–20). We have in a previous report shown that the troponin
T level identified low, intermediate and high risk groups for
death or MI during the subsequent 5 months in patients with
unstable CAD (9). This probably mirrors differences in severity
or underlying mechanisms of the disease, which might have
importance for the effects of treatment in general and heparins
in particular.
Heparins inhibit the generation of thrombin, low molecular
weight heparin mainly by inhibiting factor Xa (21), thus
preventing thrombus formation and, ultimately, the develop-
ment of MI. A reactivation phenomenon after cessation of
short-term heparin treatment has previously been demon-
strated (22). The rationale for the prolonged treatment period
in the FRISC trial was that treatment with a low dose
dalteparin would give sufficient protection until the plaque
fissure, which triggered the activation of the coagulation
system, had healed. To obtain maximal benefit and compliance
in relation to cost, it is important to be able to identify the
target patients for this rather demanding treatment with
self-administration of subcutaneous injections over several
weeks or months. The results of the present study showed that
troponin T determinations might contribute to the identifica-
tion of patients in whom long-term dalteparin treatment would
be beneficial.
Effects of dalteparin treatment in relation to troponin T
level. The event rate in the total dalteparin group was reduced
by;65% during the short-term phase of treatment. During the
long-term treatment phase the absolute reduction was main-
tained, but there was no further reduction. However, in the
subgroup with troponin T levels $0.1 mg/liter, not only was
there an effect of dalteparin treatment during the short-term
treatment phase, but also an additive effect during the long-
term treatment phase. In contrast, there seemed to be no
protective effect of long-term dalteparin in patients with very
low or undetected levels of troponin T (,0.1 mg/liter). Treat-
ment with dalteparin reduced the risk of events in patients with
a troponin T level $0.1 mg/liter almost to the same level as in
Table 3. Univariate and Multivariate Logistic Regression Analysis
Evaluating the Effect of Randomized Treatment, Troponin T Level
and Interaction Between Treatment and Troponin T Level on the
Rate of Death or Myocardial Infarction During 40 Days of
Follow-Up (n 5 971)
Variable Analyzed
Myocardial Infarction
or Death
Univariate
(p value)
Multivariate
(p value)
Treatment (placebo/dalteparin) 0.03 NS
Troponin T (,0.1/$0.1 mg/liter) 0.004 0.003
Interaction term (treatment by troponin T) 0.0017 0.007
Table 2. Effect of Dalteparin on the Rate of Death or Myocardial Infarction in Relation to Troponin T Level ,0.1 or $0.1 mg/liter at
Inclusion (n 5 971)
Troponin T
(placebo/dalteparin)
Death/MI, Day 6 Death/MI, Day 40 Death/MI, Day 150
Placebo
[no. (%)]
Dalteparin
[no. (%)]
RR
(95% CI)
Placebo
[no. (%)]
Dalteparin
[no. (%)]
RR
(95% CI)
Placebo
[no. (%)]
Dalteparin
[no. (%)]
RR
(95% CI)
,0.1 mg/liter (170/157) 4 (2.4) 0 (0) p 5 0.12 8 (4.7) 9 (5.7) 1.22 10 (5.9) 14 (8.9) 1.52
(0.48–3.1) (0.69–3.31)
$0.1 mg/liter (318/326) 19 (6.0) 8 (2.5) 0.41 45 (14.2) 24 (7.4) 0.52 65 (20.4) 52 (16.0) 0.78
(0.18–0.92) (0.32–0.83) (0.56–1.09)
CI 5 confidence interval; MI 5 myocardial infarction; RR 5 relative risk.
46 LINDAHL ET AL. JACC Vol. 29, No. 1
ANTITHROMBOTIC TREATMENT AND TROPONIN T January 1997:43–8
the low risk patients with a troponin T level ,0.1 mg/liter
(Table 2, Fig. 1). There was no further relation between the
effect of dalteparin and troponin T above the level of 0.1
mg/liter. There were no differences in clinical characteristics
between the placebo and dalteparin groups within each tropo-
nin T subset that could explain these results (Table 1). The
interaction analysis further supported that there was a real
difference in effect of dalteparin treatment in patients with and
without elevation of troponin T. Even if restricted to the UA
group, a cut-off value of 0.1 mg/liter seemed to stratify the
patients in the same way as in the total material. The inclusion
samples of troponin T obtained in the present study might not
be translated in clinical practice to admission samples, but
rather to samples obtained during the first 24 h after admission
since the median delay to inclusion (and first blood sample)
from onset of the last episode of chest pain was 24 h, whereas
the median delay to admission was only 5 h. Thus, a troponin
T level $0.1 mg/liter during the first day seems to be a useful
criterion for selecting potential candidates for long-term treat-
ment with dalteparin in patients with unstable CAD. However,
this stratification needs to be confirmed and also tested for its
applicability to other medical or interventional therapies in
unstable CAD in further studies.
How might the difference in the protective effect of long-
term dalteparin in patients with “normal” and increased levels
of troponin T be explained? It is more difficult to show a
beneficial effect of any treatment in low risk groups. The lack
of prophylactic long-term effect of dalteparin in the group of
patients with a troponin T level ,0.1 mg/liter might therefore
be a play of chance, as evident from the broad confidence
interval (Table 2). A substantially larger number of patients,
versus the number included in the present study, is necessary to
exclude a small beneficial effect. However, in such a low risk
population it is doubtful that a small beneficial effect will
outweigh the risks and costs. It might also be speculated that
the lack of protective effect of long-term dalteparin in unstable
CAD patients with normal troponin T levels might imply that
other mechanisms, besides a thrombotic process, might cause
the symptoms in these patients, e.g., coronary vasoconstriction
due to impaired endothelial vasoactive function in the athero-
sclerotic coronary arteries (23,24). Thus, in patients with
elevation of troponin T an embolizing or at least temporary
occluding red thrombus might be the main mechanism that
responds to low molecular weight heparin (5). In contrast, in
patients without troponin T elevation this process might be less
prominent and therefore less responsive to this kind of ther-
apy.
Clinical implications. Analysis of troponin T during the
first day after admission might identify patients with unstable
CAD in whom prolonged antithrombotic treatment, e.g., with
dalteparin, is beneficial. Any beneficial effect, at least of
clinical significance, of long-term dalteparin treatment seemed
to be restricted to patients with an elevation of troponin T
$0.1 mg/liter. Thus, in the selection of a long-term treatment
strategy for the individual patient with unstable CAD, this
simple, inexpensive and rapid biochemical test might be useful.
We thank the clinical staff of each center involved for their skillful assistance.
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